2024 年第 5 期 第 19 卷

疏肝健脾补髓方防治多腺苷二磷酸核糖聚合酶抑制剂维持治疗卵巢癌所致血液毒性的效果观察

Observation on the effect of Shugan Jianpi Busui decoction on prevention and treatment of blood toxicity caused by poly (adenosine diphosphate-ribose) polymerase inhibitors in maintenance treatment of ovarian cancer

作者：戴波1 姚昌菊1 郑磊2 吴悦2 张梅2

英文作者：Dai Bo1 Yao Changju1 Zheng Lei2 Wu Yue2 Zhang Mei2

单位：1安徽中医药大学，合肥230038；2安徽医科大学第一附属医院中西医结合肿瘤科，合肥230022

英文单位：1Anhui University of Chinese Medicine Hefei 230038 China; 2Oncology Department of Integrated Traditional Chinese and Western Medicine the First Affiliated Hospital of Anhui Medical University Hefei 230022 China

关键词：卵巢癌；疏肝健脾补髓方；多腺苷二磷酸核糖聚合酶抑制剂；血液毒性

英文关键词：Ovariancancer;ShuganJianpiBusuidecoction;Poly(adenosinediphosphate-ribose)polymeraseinhibitor;Bloodtoxicity

• 摘要：

• 目的  观察疏肝健脾补髓方防治多腺苷二磷酸核糖聚合酶抑制剂（PARPi）维持治疗卵巢癌所致血液毒性的效果。方法  选取2021年8月至2023年12月就诊于安徽医科大学第一附属医院中西医结合肿瘤科及医联体科室符合纳入标准的卵巢癌患者60例，按照随机数字表法分为观察组（30例）及对照组（30例）。对照组予以PARPi维持治疗，观察组在对照组基础上联合疏肝健脾补髓方同步治疗。治疗3个月后比较2组血液毒性发生率、严重程度、持续时间、中医证候积分及疗效、不良反应情况。结果  治疗3个月后，观察组贫血、血小板减少及中性粒细胞减少发生率［26.7%(8/30)比53.3%(16/30)、23.3%(7/30)比50.0%(15/30)、20.0%(6/30)比46.7%(14/30)］及严重程度均低于对照组，差异均有统计学意义（均P＜0.05）。观察组贫血及血小板减少的持续时间均短于对照组［（2.56±1.33）d比（4.21±2.00）d、（7.33±0.38）d比（9.26±1.22）d］，差异均有统计学意义（均P＜0.05）。治疗3个月后，观察组中医证候积分明显低于对照组，中医证候疗效好于对照组，差异均有统计学意义（均P＜0.05）。观察组恶心呕吐、腹泻、便秘发生情况轻于对照组（均P＜0.05）。结论  疏肝健脾补髓方可减轻血液毒性发生率及严重程度，缩短发生时间，同时改善患者中医证候疗效，安全性尚可，维护了PARPi治疗的应答持续性。

• Objective  To observe the effect of Shugan Jianpi Busui decoction on prevention and treatment of blood toxicity caused by poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) in maintenance treatment of ovarian cancer. Methods  A total of 60 patients with ovarian cancer who met the inclusion criteria were enrolled in the Oncology Department of Integrated Traditional Chinese and Western Medicine and the Department of Medical Consortium of the First Affiliated Hospital of Anhui Medical University from August 2021 to December 2023 were selected, and they were divided into observation group (30 cases) and control group (30 cases) according to the random number table method. The control group was treated with PARPi maintenance treatment, and the observation group was treated with Shugan Jianpi Busui decoction on the basis of the control group. After 3 months of treatment, the incidence, severity, duration, traditional Chinese medicine (TCM) syndrome score, efficacy and adverse reactions of the two groups were compared. Results  After 3 months of treatment, the incidence and severity of anemia, thrombocytopenia and neutropenia in the observation group were lower than those in the control group ［26.7%(8/30) vs 53.3%(16/30), 23.3%(7/30) vs 50.0%(15/30), 20.0%(6/30) vs 46.7%(14/30)］(all P＜0.05). The duration of anemia and thrombocytopenia in the observation group were shorter than those in the control group ［(2.56±1.33)d vs (4.21±2.00)d, (7.33±0.38)d vs (9.26±1.22)d］(both P＜0.05). After 3 months of treatment, the TCM syndrome score of the observation group was significantly lower than that of the control group, and the TCM syndrome curative effect was better than that of the control group (both P＜0.05). The incidence of nausea and vomiting, diarrhea and constipation in the observation group were lighter than those in the control group (all P＜0.05). Conclusion  Shugan Jianpi Busui decoction can reduce the incidence and severity of blood toxicity, shorten the occurrence time, improve the efficacy of TCM syndromes, and maintain the persistence of response to PARPi treatment.